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Abstrat: We are interested in optimizing the o-administration of two drugs for some aute
myeloid leukemias (AML), and we are looking for in vitro protools as a rst step. This issue an
be formulated as an optimal ontrol problem. The dynamis of leukemi ell populations in ulture
is given by age-strutured partial dierential equations, whih an be redued to a system of delay
dierential equations, and where the ontrols represent the ation of the drugs. The objetive
funtion relies on eigenelements of the unontrolled model and on general relative entropy, with
the idea to maximize the eieny of the protools. The onstraints take into aount the toxiity
of the drugs. We present in this paper the modeling aspets, as well as theoretial and numerial
results on the optimal ontrol problem that we get.
Key-words: Aute myeloid leukemia, optimal ontrol, delay dierential equations, population
dynamis, general relative entropy, in vitro therapeuti optimization
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Contrle optimal de dynamique de populuations de ellules
leuémiques
Résumé : Nous sommes intéressés par optimiser la o-administration de deux médiaments
pour ertaines leuémies aigües myéloïdes (LAM) et nous herhons des protooles d'administra-
tion in vitro dans un premier temps. Cela peut se formuler omme un problème de ontrle
optimal. La dynamique de populations de ellules leuémiques en ulture est donnée par des équa-
tions aux dérivées partielles struturées en âge, qui peuvent se ramener à un système d'équations
diérentielles à retards, et où les ontrles représentent l'ation des médiaments. La fontion
objetif est dénie à partir d'éléments propres du modèle non ontrlé et d'un prinipe d'entropie
relative généralisée, ave l'idée de maximiser l'eaité des protooles. Les ontraintes prennent
en ompte la toxiité des médiaments. Nous présentons dans e rapport les aspets de mod-
élisation, ainsi que des résultats théoriques et numériques sur le problème de ontrle optimal
obtenu.
Mots-lés : Leuémies aigües myéloïdes, ontrle optimal, équations diérentielles à re-
tards,dynamique de populations, entropie relative généralisée, optimisation thérapeutique in
vitro
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1 Introdution
Aute myeloid leukemias (AML) are aners of the myeloid lineage of white blood ells. The pro-
ess of blood prodution, alled hematopoiesis, takes plae in the bone marrow, with hematopoi-
eti stem ells (HSC) at its root. HSC have the abilty to self-renew, i.e. to divide without dif-
ferentiating, and to dierentiate towards any lineage of blood ells by dividing into progenitors.
These progenitors are ommitted stem ells whih follow a path of dienrentiation, produing
ells whih are more and more engaged into one lineage and lose progressively their ability to
self-renew. One they are fully mature and funtional, ells of eah lineage are released into
the bloodstream. The hematopoiesis onsists in the regulation of the self-renewal and the dif-
ferentiation of ell populations [22℄. In AML, the dierentiation is bloked at some early stage,
leading to the aumulation of immature white blood ells, alled blasts, of the myeloid lineage.
This blokade being assoiated with a proliferation advantage, the blasts quikly rowd the bone
marrow and are eventually released into the bloodstream.
One of the rst mathematial model on hematopoiesis was proposed in 1978 by Makey and
foused on the HSC population dynamis [18℄. Makey onsidered two phases in his model,
a resting phase and a proliferating phase, and desribed the dynamis of the two HSC sub-
populations by a system of delay dierential equations; these equations an be justied by age-
strutured partial dierential equations. To represent the blokade of the dierentiation in
AML, Adimy et al. onsidered the dynamis of ell populations of several maturity stages and
developped a multi-ompartmental model, where eah ompartment represents a maturity stage
and is again divided in two phases [2℄. Özbay et al. proeeded with the stabiliy analysis of
this delay dierential system in [21℄, and Avila et al. rened the model in [3℄ by onsidering
more than two phases per ompartement and modeling the fast proliferation in AML. Stiehl
and Mariniak also proposed a multi-ompartmental model on leukemias [25℄; they onsidered
healthy and leukemi ell populations, but did not distinguish resting and proliferating phases
and thus did not get delays.
The treatment for most of the types of AML is a hallenge [24℄. Cliniians of the depart-
ment of hematology at Saint-Antoine hospital in Paris would be interested for some ases in
o-administrating two drugs: a ytotoxi (Araytin), whih enhanes ell death, and a ytostati
(AC200), whih slows down proliferation. A rst step is to determine how suh a ombination
should be sheduled in in vitro experiments. To that purpose, biologists of the same hospital
have sampled blood from patients with AML, sorted aner blasts, and arried out leukemi ell
ultures. The number of ells, their state in the ell yle, and their maturity stage have then
been daily measured during 5 days, without and with eah of the two drugs at dierent onstant
onentrations in the ulture [4℄.
In this paper, we idealize these experiments and onsider leukemi ell ultures with varying
onentration of both drugs. We are looking for in vitro protools of drugs administration, i.e.
shedules of the onentration of both drugs during the experiment, whih are as eient as
possible without being too toxi. To formulate this issue as an optimal ontrol problem, a state
equation, an objetive funtion, and onstraints have to been set.
The state equation models the ell population dynamis under the ation of the drugs; we
onsider an age-strutured model with one maturity ompartement, divided in one resting phase
and one proliferating phase. Adimy and Crauste used suh a model in [1℄ to represent the
dependene of ell death and proliferation on growth fators. Here, the ation of the ytotoxi on
ell death is age-dependent, and the drug onentrations are not solutions of evolution equations
but are ontrol variables whih dene an in vitro protool. Gabriel et al. identied the ation
of a drug induing quiesene (erlotinib) with a fration of quiesent ells in [11℄. The ation
of the ytostati in our model is also represented by a fration of resting ells, whih is here
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time-dependent, and not by a varying veloity in the proliferating phase as Hinow et al. in [15℄.
See also [6℄ about the modeling of the ation of the drugs.
The objetive funtion aims at minimizing the leukemi ell population at the end of the
experiment, in order to maximize the eieny of the orresponding protool. Its denition
atually requires a long time asymptoti analysis to avoid an horizon eet. This analysis relies
on the speialization of the general relative entropy priniple introdued by Mihel et al. [20℄ to
our model. Various kinds of objetive funtions exist in the litterature: nal or maximal number
of tumor ells [5℄, nal tumor volume [16℄, performane index [17℄, or eigenvalue [7℄; the use of
an age-dependent weight given by eigenelements in this paper seems to be new.
The onstraints ome from biologial bounds on the ation of the drugs and from maximal
umulative doses that we impose to limit the toxiity of the protools, as in [16℄; there is no
healthy population in our model on whih we ould set a toxiity threshold as in [5, 7℄. The
optimization problem that we get is equivalent, by the method of harateristis, to an optimal
ontrol problem of delay dierential equations. For suh a problem, optimality onditions are
available in the form of Pontryagin's minimum priniple [14℄; it an also be redued to an
undelayed optimal ontrol problem [12, 13℄, and then solved numerially by standard solvers.
The paper is organized as follows. In Setion 2, we model the population dynamis under the
ation of the drugs. Setion 3 ontains the analysis of this model, inluding a general relative
entropy priniple and a long time asymptoti analysis. The optimal ontrol problem is set in
Setion 4, and theoretial results and numerial optimal protools are presented in Setion 5.
The preise statement of Pontryagin's minimum priniple for our problem has been postponed
to the appendix, together with the parameters used for the numerial resolutions.
2 Modeling
We present here the dynamis of leukemi ell populations in ulture and under the ation of
the two drugs.
2.1 Cell populations
We onsider a leukemi ell population, in vitro, and we distinguish two sub-populations [1, 18℄:
the resting ells, whih are inative (G0 phase), and the proliferating ells, whih are engaged in
their yle (G1SG2M phase).
Resting ells are introdued into the proliferating phase at a rate β, independently of the time
spent in the resting phase. Considering that the proliferation is unontrolled in ase of AML, we
do not represent any feedbak from a ell population [18, 19℄ or a growth fator [1℄, and thus β
is onstant in our model.
Proliferating ells die by apoptosis at a rate γ, and if it does not die, a ell divide during
mitosis, after a time 2τ spent in the phase, in two daughter ells whih enter the resting phase.
We onsider that the duration of the proliferating phase 2τ is the same for all ells ; this is not
true biologially [2℄ but one an think of 2τ as an average duration [19℄.
We struture the proliferating population by an age variable a whih represents the time
spent in the proliferating phase by a ell. We denote by R(t) the resting population at time t,
and by p(t, a) the proliferating population density with age a at time t.
2.2 Ation of the drugs
The two drugs are a ytotoxi (Araytin) and a ytostati (AC220).
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The ytotoxi damages the DNA of the ells during the S sub-phase of their yle; it results
in an extra death rate. To simplify further alulus and numerial issues, we onsider that u(t),
the death rate due to the ytotoxi at time t, aets the seond-half of the proliferating phase,
i.e. proliferating ells with age a ∈ [τ, 2τ ].
The ytostati inhibits a reeptor tyrosine kynase (Flt3) of the ells in the resting phase; it
results in a fration k(t) of inhibited ells among the resting ells, whih an no more enter the
proliferating phase. The global introdution rate to the proliferating phase at time t is then
(1 − k(t))β.
τ τ
(1 − k(t))β
γ γ + u(t)
R(t)p(t, a)
proliferating phase resting phase
×2
Figure 1: The model.
We denote by v(t) the inhibition rate due to the ytostati at time t, and by α the rate of
natural dis-inhibition. We onsider that the dynamis of k is given by
dk
dt
(t) = v(t)(1 − k(t))− αk(t). (1)
The ation rates due to the drugs are inreasing funtions of their onentration in the ell
ulture, the latter being hosen during in vitro experiments. Thus we onsider that we ontrol
diretly the ation rates u and v.
2.3 The age-strutured model
The dynamis of the ell populations is given by the following partially age-strutured system:
dR
dt
(t) = −(1− k(t))βR(t) + 2p(t, 2τ) (2)
∂p
∂t
(t, a) +
∂p
∂a
(t, a) = −(γ+χ(τ,2τ)(a)u(t))p(t, a) 0 < a < 2τ (3)
p(t, 0) = (1− k(t))βR(t) (4)
The equation (2) is a balane equation for the resting phase between the outward and inward
ow; the transport equation (3) desribes the evolution of the age ohorts of proliferating ells,
sine they are aging with veloity 1; the boundary ondition (4) gives the inward ow to the
proliferating phase.
RR n° 8356
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2.4 A ontrolled version of Makey's model
We denote by P and P2 the total proliferating population and sub-population in the seond-half
of the phase, respetively:
P (t) :=
∫ 2τ
0
p(t, a)da, P2(t) :=
∫ 2τ
τ
p(t, a)da.
Formally, and this ould be justied with the results of Setion 3, if we dierentiate P, P2 and
use the method of harateristis as in [1℄, we derive from (1)-(4) the following system of delay
dierential equations:
dR
dt
(t) = −(1− k(t))βR(t) + 2(1− k(t− 2τ))βR(t− 2τ)e−(γ2τ+
∫
t
t−τ
u(s)ds)
(5)
dP
dt
(t) = −(γP (t) + u(t)P2(t)) + (1− k(t))βR(t) (6)
− (1 − k(t− 2τ))βR(t − 2τ)e−(γ2τ+
∫
t
t−τ
u(s)ds)
dP2
dt
(t) = −(γ + u(t))P2(t) + (1− k(t− τ))βR(t − τ)e
−γτ
(7)
− (1 − k(t− 2τ))βR(t − 2τ)e−(γ2τ+
∫
t
t−τ
u(s)ds)
dk
dt
(t) = v(t)(1 − k(t))− αk(t) (8)
Unsurprisingly, we get a ontrolled version of Makey's 1978 model [18℄. The original model is a
system of two dierential equations with one disrete delay, and a nonlinearity in β; it is one of
the rst mathematial model of the dynamis of hematopoieti stem ells (HSC), whih are at
the root of the hematopoiesis, the proess of blood prodution. We have in (5)-(8) two ontrol
variables, u and v, and two extra state variables, P2 and k, beause of the ontrols.
As we will explain in Setion 4.1, the age-struture in the proliferating population atually
matters, and thus it is of interest to analyse the age-strutured model (2)-(4).
3 Analysis of the age-strutured model
3.1 Existene of solutions
Given (β, γ) ∈ L∞loc(0,∞)× L
∞
loc((0,∞)× (0, 2τ)) and (R0, p0) ∈ R× L
∞(0, 2τ), we onsider the
system
dR
dt
(t) = −β(t)R(t) + 2p(t, 2τ) 0 < t (9)
∂p
∂t
(t, a) +
∂p
∂a
(t, a) = −γ(t, a)p(t, a) 0 < t, 0 < a < 2τ (10)
p(t, 0) = β(t)R(t) 0 < t (11)
with the initial ondition
R(0) = R0, p(0, ·) = p0. (12)
We follow [10℄ for the notion of solution.
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Denition 3.1. We say that (10) holds along the harateristis a.e. if and only if there holds,
for a.a. (t, a) ∈ (0,∞)× (0, 2τ),
p(s, a+ s) = p(0, a)−
∫ s
0
(γp)(θ, a+ θ)dθ for a.a. s ∈ (0, 2τ − a), (13)
p(t+ s, s) = p(t, 0)−
∫ s
0
(γp)(t+ θ, θ)dθ for a.a. s ∈ (0, 2τ). (14)
Lemma 3.2. If p ∈ L∞loc((0,∞) × (0, 2τ)) is suh that (10) holds along the harateristis a.e.,
then p is Lipshitz along the harateristis {t − a = c} for a.a. c, t 7→
∫ 2τ
0
p(t, a)da is loally
Lipshitz and there holds a.e.
d
dt
∫ 2τ
0
p(t, a)da = p(t, 0)− p(t, 2τ)−
∫ 2τ
0
(γp)(t, a)da.
Proof. The rst assertion follows from (13)-(14). For the last two assertions, it is enough to
ompute
∫ 2τ
0 p(t, a)da using the same relations.
Denition 3.3. A solution of (9)-(12) is any
(R, p) ∈W 1,∞loc (0,∞)× L
∞
loc((0,∞)× (0, 2τ))
suh that (9) holds a.e., (10) holds along the harateristis a.e., (11) holds a.e., and (12) holds.
Lemma 3.4. Given any (β, γ) and (R0, p0), there exists a unique solution (R, p) of (9)-(12). If
(β, γ) and (R0, p0) are non-negative, then (R, p) is non-negative. Moreover, dening
Γ: (t, a) 7→
{∫ t
0 γ(s, a− t+ s)ds if 0 < t < a < 2τ,∫ a
0
γ(t− a+ s, s)ds if 0 < a < 2τ, a < t,
if β, Γ, p0 are loally Lipshitz and p0(0) = β(0)R0, then p is loally Lipshitz and R ∈ W
2,∞
loc .
Proof. For a.a. c ∈ (−2τ, 0), p is determined on {t− a = c} by
p(t, a) = p0(a− t)e
−
∫
t
0
γ(s,a−t+s)ds.
Then (9) beomes a linear ODE on (0, 2τ), from whih we get R, and then p on {t− a = c} for
a.a. c ∈ (0, 2τ), and so on. The sign of (R, p) follows.
Observe that a.e. on {t− a > 0},
p(t, a) = β(t− a)R(t− a)e−
∫
a
0
γ(t−a+s,s)ds.
The ontinuity of p on {t− a = 0} is equivalent to p0(0) = β(0)R0.
3.2 General relative entropy
We introdue the dual system assoiated with (9)-(11)
dΨ
dt
(t) = β(t)Ψ(t) − β(t)φ(t, 0) 0 < t (15)
∂φ
∂t
(t, a) +
∂φ
∂a
(t, a) = γ(t, a)φ(t, a) 0 < t, 0 < a < 2τ (16)
φ(t, 2τ) = 2Ψ(t) 0 < t (17)
RR n° 8356
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Solutions of (15)-(17) are dened as for the primal system, see Denition 3.3.
Adapting [20℄ to our model, we get a general relative entropy priniple. Let (β, γ) be xed.
Given a solution (R, p) and a positive solution (Rˆ, pˆ) of (9)-(11), a positive solution (Ψ, φ) of
(15)-(17), and H ∈ L∞loc(R), we dene H by
H(t) := Ψ(t)Rˆ(t)H
(
R(t)
Rˆ(t)
)
+
∫ 2τ
0
φ(t, a)pˆ(t, a)H
(
p(t, a)
pˆ(t, a)
)
da.
Theorem 3.5 (General Relative Entropy). Let H be loally Lipshitz and dierentiable every-
where. Then H is loally Lipshitz and there holds a.e.
dH
dt
(t) = φ(t, 2τ)pˆ(t, 2τ)
[
H
(
p(t, 0)
pˆ(t, 0)
)
−H
(
p(t, 2τ)
pˆ(t, 2τ)
)
+H ′
(
p(t, 0)
pˆ(t, 0)
)(
p(t, 2τ)
pˆ(t, 2τ)
−
p(t, 0)
pˆ(t, 0)
)]
. (18)
Corollary 3.6. Let H be onvex, possibly non dierentiable. Then H is non-inreasing.
Proof of Corollary 3.6. Let H be onvex. Then H is loally Lipshitz and has left and right
derivatives everywhere. Then, as in the proof of Theorem 3.5, H is loally Lipshitz and (18)
holds a.e. if we replae the derivative of H by its right derivative and the derivative of H by its
left or right derivative, depending on the sign of the right derivative of
p(t,0)
pˆ(t,0) . Observe now that
this right-hand side of (18) is non-positive if H is onvex.
Proof of Theorem 3.5. Observe that, along the harateristis a.e., there holds(
∂
∂t
+
∂
∂a
)
φ(t, a)pˆ(t, a) = 0,
(
∂
∂t
+
∂
∂a
)
p(t, a)
pˆ(t, a)
= 0,
and then (
∂
∂t
+
∂
∂a
)
φ(t, a)pˆ(t, a)H
(
p(t, a)
pˆ(t, a)
)
= 0.
By Lemma 3.2, the seond term of H is loally Lipshitz, with derivative a.e.
φ(t, 0)pˆ(t, 0)H
(
p(t, 0)
pˆ(t, 0)
)
− φ(t, 2τ)pˆ(t, 2τ)H
(
p(t, 2τ)
pˆ(t, 2τ)
)
.
The rst term of H is obviously loally Lipshitz, and a.e.(
d
dt
Ψ(t)Rˆ(t)
)
H
(
R(t)
Rˆ(t)
)
=
(
− β(t)φ(t, 0)Rˆ(t) + Ψ(t)2pˆ(t, 2τ)
)
H
(
R(t)
Rˆ(t)
)
=
(
− φ(t, 0)pˆ(t, 0) + φ(t, 2τ)pˆ(t, 2τ)
)
H
(
p(t, 0)
pˆ(t, 0)
)
,
and
Ψ(t)Rˆ(t)
d
dt
H
(
R(t)
Rˆ(t)
)
= Ψ(t)Rˆ(t)H ′
(
R(t)
Rˆ(t)
)
1
Rˆ(t)
(
dR
dt
(t)−
R(t)
Rˆ(t)
dRˆ
dt
(t)
)
= Ψ(t)H ′
(
p(t, 0)
pˆ(t, 0)
)(
2p(t, 2τ)−
p(t, 0)
pˆ(t, 0)
2pˆ(t, 2τ)
)
= φ(t, 2τ)pˆ(t, 2τ)H ′
(
p(t, 0)
pˆ(t, 0)
)(
p(t, τ)
pˆ(t, τ)
−
p(t, 0)
pˆ(t, 0)
)
.
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3.3 Eigenelements
Let β > 0 and γ ≥ 0 be onstant. Looking for partiular solutions of (9)-(11) and (15)-(17) of
the form
R : t 7→ R¯eλt Ψ: t 7→ Ψ¯e−λt
p : (t, a) 7→ p¯(a)eλt φ : (t, a) 7→ φ¯(a)e−λt
with λ ∈ R and p¯, φ¯ dierentiable, we get the following eigenvalue problem:
(λ+ β)R¯ = 2p¯(2τ) (λ+ β)Ψ¯ = βφ¯(0) (19)
dp¯
da
(a) = −(λ+ γ)p¯(a)
dφ¯
da
(a) = (λ+ γ)φ¯(a) (20)
p¯(0) = βR¯ φ¯(2τ) = 2Ψ¯ (21)
Equations (20)-(21) give
p¯(a) = βR¯e−(λ+γ)a, φ¯(a) = 2Ψ¯e(λ+γ)(a−2τ). (22)
If R¯, Ψ¯ 6= 0, (19) is then equivalent to
λ+ β = 2βe−(λ+γ)2τ . (23)
Theorem 3.7 (First eigenelements). There exists a unique solution (λ,R¯, p¯,Ψ¯, φ¯) of (19)-(21)
suh that
R¯ > 0, p¯ > 0, R¯+
∫ 2τ
0
p¯(a)da = 1,
Ψ¯ > 0, φ¯ > 0, Ψ¯R¯+
∫ 2τ
0
φ¯(a)p¯(a)da = 1.
Proof. It is enough to observe that (23) has a unique real solution.
3.4 Long time asymptoti
3.4.1 without the ation of the drugs
We onsider here that there is no ation of the drugs for t > 0, i.e. that β > 0 and γ ≥ 0 are
onstant. The rst eigenelements (λ, R¯, p¯, Ψ¯, φ¯) are given by Theorem 3.7.
Theorem 3.8. Let (R0, p0) be an initial ondition, C > 0 be suh that
|R0| ≤ CR¯, |p0(·)| ≤ Cp¯(·),
and (R, p) be the solution of (9)-(12). Then, for all t > 0,
|R(t)| ≤ CR¯eλt, |p(t, ·)| ≤ Cp¯(·)eλt, (24)(
Ψ¯R(t) +
∫ 2τ
0
φ¯(a)p(t, a)da
)
e−λt = Ψ¯R0 +
∫ 2τ
0
φ¯(a)p0(a)da := ρ, (25)(
Ψ¯|R(t)|+
∫ 2τ
0
φ¯(a)|p(t, a)|da
)
e−λt ≤ Ψ¯|R0|+
∫ 2τ
0
φ¯(a)|p0(a)|da, (26)
lim
t→∞
(
Ψ¯|R(t)e−λt − ρR¯|+
∫ 2τ
0
φ¯(a)|p(t, a)e−λt − ρp¯(a)|da
)
= 0. (27)
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Remark 3.9. Theorem 3.8 gives an interpretation of the rst eigenelements: for the L1 topology,(
R(t), p(t, ·)
)
∼ ρ
(
R¯eλt, p¯(·)eλt
)
as t → ∞, with ρ given by (25). Then the rst eigenvalue λ is the Malthus parameter of
the model, whih gives the overall exponential growth or deay of the population. We derive
from its denition (23) that λ has the same sign as 2e−γ2τ − 1, whih is the proliferating phase
balane. Asymptotially, any solution beomes proportional to a partiular solution with age
prole given by the rst primal eigenvetor (R¯, p¯) and rate of time evolution λ. The oeient
of proportionality ρ is determined initially with the rst dual eigenvetor (Ψ¯, φ¯).
Proof. We follow the same sheme as in [20, 23℄. We apply the general relative entropy priniple
to (R, p), (R¯eλt, p¯eλt), (Ψ¯e−λt, φ¯e−λt), and to the following onvex funtions:
 H(h) := (h± C)
2
+ for (24). The two orresponding entropies H are non-inreasing by
Corollary 3.6, non-negative, and initially null; then they are null everywhere.
 H(h) := h for (25); H is onstant by Theorem 3.5.
 H(h) := |h| for (26); H is non-inreasing by Corollary 3.6.
 H(h) := |h − ρ| for (27); H is non-inreasing by Corollary 3.6 and non-negative. Then it
has a limit L, i.e.(
Ψ¯|R(t)e−λt − ρR¯|+
∫ 2τ
0
φ¯(a)|p(t, a)e−λt − ρp¯(a)|da
)
→ L (28)
as t→∞. It remains to prove that L = 0; we do that in several steps.
1. Let pk0 , k ∈ N, be Lipshitz, with p
k
0(0) = βR0 and suh that, as k →∞,
εk :=
∫ 2τ
0
φ¯(a)
∣∣pk0(a)− p0(a)∣∣ da→ 0.
Let (Rk, pk) be the solution of (9)-(11) with initial ondition (R0, p
k
0), ρk be given by
(25), and Lk be given by (28). Then |ρk − ρ| ≤ εk, and applying (26) to the solution
(Rk −R, pk − p) of (9)-(11), we get(
Ψ¯|Rk(t)−R(t)|+
∫ 2τ
0
φ¯(a)|pk(t, a)− p(t, a)|da
)
e−λt ≤ εk
for all t. Then L ≤ Lk + 2εk, and it is enough to show that L = 0 for an initial ondition
(R0, p0) with p0 Lipshitz and p0(0) = βR0, as we assume in the sequel of the proof.
2. Sine β and γ are onstant, (R, p) ∈ W 2,∞loc ×W
1,∞
loc by Lemma 3.4. We observe moreover
that (dRdt ,
∂p
∂t
) is a solution of (9)-(11). Then by (24), there exists C′ > 0 suh that for all
t, ∣∣∣∣dRdt (t)
∣∣∣∣ ≤ C′R¯eλt, ∣∣∣∣∂p∂t (t, ·)
∣∣∣∣ ≤ C′p¯(·)eλt. (29)
It follows by (10) that for all t,∣∣∣∣∂p∂a (t, ·)
∣∣∣∣ ≤ (γC + C′)p¯(·)eλt. (30)
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3. We apply again Theorem 3.5 to (R, p), (R¯eλt, p¯eλt), (Ψ¯e−λt, φ¯e−λt), and toH(h) := (h−1)2.
Using that
H(h1)−H(h2) +H
′(h1)(h2 − h1) = −(h1 − h2)
2,
we get for the orresponding H
dH
dt
(t) = −φ¯(2τ)p¯(2τ)
(
p(t, 2τ)e−λt
p¯(2τ)
−
p(t, 0)e−λt
p¯(0)
)2
.
Then
dH
dt is globally Lipshitz by (24) and (29), and non-positive. Sine H is bounded
below by 0, it has a limit and then dHdt (t)→ 0, i.e.
p(t, 2τ)e−λt
p¯(2τ)
−
p(t, 0)e−λt
p¯(0)
→ 0 (31)
as t→∞.
4. We dene (Qk, nk) ∈ C([0, 1])× C([0, 1]× [0, 2τ ]), k ∈ N, by
Qk(t) := R(t+ k)e−λ(t+k), nk(t, a) := p(t+ k, a)e−λ(t+k).
We derive from (24),(29)-(30) and Arzelà-Asoli theorem that there exists (Q¯, n¯) suh that,
up to a subsequene, (Qk, nk)→ (Q¯, n¯) uniformly. Then for all t ∈ [0, 1],
Ψ¯Q¯(t) +
∫ 2τ
0
φ¯(a)n¯(t, a)da = ρ, (32)
Ψ¯|Q¯(t)− ρR¯|+
∫ 2τ
0
φ¯(a)|n¯(t, a)− ρp¯(a)|da = L, (33)
n¯(t, 2τ)
p¯(2τ)
−
n¯(t, 0)
p¯(0)
= 0 (34)
by (25), (28), and (31), respetively. Moreover (Q¯, n¯) is solution, in the sense of Deni-
tion 3.3, of
dQ
dt
(t) = −(λ+ β)Q(t) + 2n(t, 2τ) 0 < t < 1 (35)
∂n
∂t
(t, a) +
∂n
∂a
(t, a) = −(λ+ γ)n(t, a) 0 < t < 1, 0 < a < 2τ (36)
n(t, 0) = βQ(t) 0 < t < 1 (37)
Injeting (34) and (37) into (35), we get
dQ¯
dt
(t) =
[
− (λ+ β)p¯(0) + 2βp¯(2τ)
] Q¯(t)
p¯(0)
= 0
by denition (22)-(23) of the eigenelements. Then Q¯ is onstant and
n¯(0, a) = lim
k
p(k, a)e−λk
= lim
k
βR(k − a)e−λ(k−a)e−(λ+γ)a
= βQ¯e−(λ+γ)a.
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Solving (36) along the harateristis, it omes that
n¯(t, a) = βQ¯e−(λ+γ)a
for all (t, a) ∈ [0, 1]× [0, 2τ ]; in partiular, n¯ does not depend on t. Observe that (Q¯, n¯) is
proportional to (R¯, p¯); by (32), (Q¯, n¯) = ρ(R¯, p¯), and then by (33), L = 0 as was to prove.
3.4.2 with the ation of the drugs
We onsider now that the drugs are not administrated for t > 0 but that they have a residual
ation. Namely, if at t = 0 there is a fration k0 ≥ 0 of inhibited ells among the resting ells,
then by (1), for t > 0,
β(t) =
(
1− k0e
−αt
)
β
with α > 0, and γ ≥ 0 is onstant. We ontinue to use the rst eigenelements given by Theo-
rem 3.7, i.e. for β onstant too.
Lemma 3.10. Assume that the rst eigenvalue λ is non-negative. Let (R0, p0) be a non-negative
initial ondition, (R, p) be the solution of (9)-(12), and I be dened by
I(t) :=
(
Ψ¯R(t) +
∫ 2τ
0
φ¯(a)p(t, a)da
)
e−λt.
Then I is loally Lipshitz, non-inreasing, and for all t > 0,
e
−λ
k0
α
(
1− e−αt
)
I(0) ≤ I(t) ≤ I(0).
In partiular, I(t) has a limit, say I∞ ∈ [e
−λ
k0
α I(0), I(0)], as t→∞.
Remark 3.11. 1. If λ ≤ 0, then we an show the reverse inequality:
I(0) ≤ I(t) ≤ e
−λ
k0
α
(
1− e−αt
)
I(0).
2. If k0 = 0, then β is onstant and we reover result (25) of Theorem 3.8: I is onstantly
equal to ρ.
3. The rst eigenvalue λ is still the Malthus parameter of the model, in the sense that
(
R(t)e−λ
′t, p(t, ·)e−λ
′t
)
→
{
0 if λ′ > λ
∞ if λ′ < λ
as t→∞.
4. If there exists ρ′ suh that, in the sense of (27),(
R(t), p(t, ·)
)
∼ ρ′
(
R¯eλt, p¯(·)eλt
)
as t→∞, then ρ′ = I∞.
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Proof. We still have, along the harateristis a.e.,(
∂
∂t
+
∂
∂a
)
φ¯(a)e−λtp(t, a) = 0.
Then as in the proof of Theorem 3.5, I is loally Lipshitz. And there holds a.e.,
dI
dt
(t) = Ψ¯ (−(λ+ β(t))R(t) + 2p(t, 2τ)) e−λt
+
(
φ¯(0)p(t, 0)− φ¯(2τ)p(t, 2τ)
)
e−λt
= −λk0e
−αtΨ¯R(t)e−λt
Sine λ, k0, R, p ≥ 0 (see Lemma 3.4), we get a.e.
−λk0e
−αtI(t) ≤
dI
dt
(t) ≤ 0.
The result follows.
4 The optimal ontrol problem
We x a time horizon T > 0 and we onsider leukemi ell ultures with varying onentrations
of both drugs on [0, T ]. As explained in Setion 2.2, we onsider that, in our in vitro model
(1)-(4), we ontrol diretly the death rate u due to the ytotoxi and the inhibition rate v due to
the ytostati. Thus we all protool of drugs administration any (u, v) ∈ L∞(0, T ;R2) satisfying
the following biologial bounds:{
0 ≤ u(t) ≤ u¯
0 ≤ v(t) ≤ v¯
for a.a. t ∈ (0, T ). (38)
Note that by Lemma 3.4, given any protool (u, v), there exists a unique assoiated state, i.e.
(R, p, k) suh that (1)-(4) hold.
We are looking for protools of drugs administration whih are as muh eient as possible,
and not too toxi. The notion of eieny will be handled by the objetive funtion (Se-
tion 4.1), and the one of toxiity by the onstraints (Setion 4.2), in our optimal ontrol problem
(Setion 4.3).
4.1 Horizon eet and age-weighted population
Sine we onsider only leukemi ells, an eient protool has to aim at the extintion of the
total population. Nevertheless, if we try to minimize the total population, i.e. if we onsider the
problem
min
(u,v,R,p,k)
(
R(T ) +
∫ 2τ
0
p(T, a)da
)
subjet to (1)-(4), (38), (39)
then we observe a horizon eet : it is always optimal to give no ytostati v at the end of the
experiment, whatever the parameters are. It an be seen numerially and proved theoretially,
and it is easily understandable: the resting ells whih are introdued into the proliferating phase
at time t ∈ (T − 2τ, T ) will not divide before T , but might die, whih is not the ase if they stay
in the resting phase; it is therefore optimal to have a high global introdution rate, i.e. a low
fration of inhibited ells k, at the end. We end up at time T with a lled proliferating phase,
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whih ows into the resting phase after T . If for example the death rate in the proliferating
phase is so low that its balane is positive, i.e. that it globally produes ells after division, then
the total population for this optimal protool beomes muh larger than for other protools (see
Figure 2), whih is not satisfying.
0 4
5
6
7
8
9
10
11
12
13
14
0 1 2 3 4 T= 5 6 7
Figure 2: An horizon eet. We onsider problem (39) with no ytotoxi u, T = 5 days,
τ = 1 day; the other parameters are given in Appendix A.3 and are suh that the proliferat-
ing phase globally produes ells. See Setion 5.2 about numerial resolution. The solid lines
(resp. the dash lines) represent the optimal protool (resp. the v¯-onstant protool) of ytostati
administration and the assoiated total population.
Resting ells and proliferating ells with dierent ages do not have the same role in the
population dynamis. Thus it is natural not to give them the same weight in the objetive
funtion. One hoie of age-dependent weight onsists in the rst dual eigenvetor (Ψ¯, φ¯), given
by Theorem 3.7; it is justied by Remarks 3.9 and 3.11. After we stop administrating the
drugs at time T , there is no ation of the ytotoxi and a residual ation of the ytostati,
as in Setion 3.4.2; nothing an be done on the Malthus parameter λ, whih is given by the
unontrolled system, but we an try to minimize the weighted total population
Ψ¯R(·) +
∫ 2τ
0
φ¯(a)p(·, a)da (40)
at time T . If there was no more ation of the ytostati after T , the weighted total population (40)
would be onstant for t > T and would give the asymptoti size of the population (Theorem 3.8).
It is not exatly the ase with the residual ation of the ytostati (Lemma 3.10), but even though
we hoose this weighted total population at time T as the objetive funtion.
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4.2 Maximal umulative doses
In order to limit the toxiity of the protools, it is useful to add onstraints on the umulative
doses of the drugs. Namely, we x U¯ , V¯ and we restrit the optimization problem to the protools
(u, v) suh that ∫ T
0
u(t)dt ≤ U¯ ,
∫ T
0
v(t)dt ≤ V¯ . (41)
Note that with the bounds (38) on the ontrols, the onstraints (41) are nontrivial i
0 < U¯ < u¯T, 0 < V¯ < v¯T,
respetively.
4.3 Redution to a problem with delays
The state of the ell ulture at the beginning of the experiments is xed; it furnishes the initial
ondition (k0, R0, p0) ∈ R× R× L
∞(0, 2τ) of (1)-(4):
k(0) = k0, R(0) = R0, p(0, ·) = p0 (42)
with k0 = 0, R0, p0 ≥ 0. The issue of nding good protools of drugs administration an nally
be formulated as the following optimal ontrol problem:
min
(u,v,R,p,k)
(
R(T ) +
∫ 2τ
0
Ψ¯−1φ¯(a)p(T, a)da
)
(43)
subjet to (1)-(4), (38), (41)-(42).
Reall that (Ψ¯, φ¯) is the rst dual eigenvetor, dened by Theorem 3.7.
Similarly to the derivation of Makey's model (Setion 2.4), (43) an be redued to an op-
timal ontrol problem of delay dierential equations. We denote by p˜, P˜ and P˜2 the weighted
proliferating population density, the total weighted proliferating population and sub-population
in the seond-half of the phase, respetively:
p˜(t, a) := Ψ¯−1φ¯(a)p(t, a),
P˜ (t) :=
∫ 2τ
0
p˜(t, a)da, P˜2(t) :=
∫ 2τ
τ
p˜(t, a)da.
Let (u, v,R, p, k) be suh that (1)-(4),(42) hold. Observe that, along the harateristis a.e.,
there holds
∂p˜
∂t
(t, a) +
∂p˜
∂a
(t, a) = (λ−χ(τ,2τ)(a)u(t))p˜(t, a).
Then by Lemma 3.2, there holds a.e.
dR
dt
(t) = −(1− k(t))βR(t) + p˜(t, 2τ) (44)
dP˜
dt
(t) = λP˜ (t)− u(t)P˜2(t) + p˜(t, 0)− p˜(t, 2τ) (45)
dP˜2
dt
(t) = (λ− u(t))P˜2(t) + p˜(t, τ) − p˜(t, 2τ) (46)
dk
dt
(t) = v(t)(1 − k(t))− αk(t) (47)
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where, by denition of λ and by the method of harateristis,
p˜(t, 0) = (1− k(t))(λ + β)R(t) (48)
p˜(t, τ) =
{
p0(τ − t)2e
−γt−(λ+γ)τ
if t < τ
(1− k(t− τ))(λ + β)R(t− τ)eλτ if t > τ
(49)
p˜(t, 2τ) =
{
p0(2τ − t)2e
−γt−y(t)
if t < 2τ
(1− k(t− 2τ))(λ + β)R(t− 2τ)eλ2τ−y(t) if t > 2τ
(50)
with y(t) :=
{∫ t
0 u(s)ds if t < τ∫ t
t−τ
u(s)ds if t > τ
.
We onsider y as a new state variable, and we also introdue two extra state variables U and V
in order to handle the integral onstraints (41):
dy
dt
(t) =
{
u(t) if t < τ
u(t)− u(t− τ) if t > τ
,
dU
dt
(t) = u(t),
dV
dt
(t) = v(t). (51)
Observe that (44)-(51) is a system of ordinary dierential equations for t < τ ; it beomes a
system of dierential equations with one disrete delay for τ < t < 2τ , and with two disrete
delays for t > 2τ . Its initial ondition is the following:
R(0) = R0, k(0) = 0, y(0) = 0, U(0) = 0, V (0) = 0,
P˜ (0) =
∫ 2τ
0
2e(λ+γ)(a−2τ)p0(a)da, P˜2(0) =
∫ 2τ
τ
2e(λ+γ)(a−2τ)p0(a)da.
(52)
Problem (43) is therefore equivalent to the following optimal ontrol problem:
min
(u,v,R,P˜ ,P˜2,k,y,U,V )
(R+ P˜ )(T ) (53)
subjet to (44)-(52),
{
0 ≤ u(t) ≤ u¯
0 ≤ v(t) ≤ v¯
for a.a. t ∈ (0, T ), and
{
U(T ) ≤ U¯
V (T ) ≤ V¯
.
5 Results and onlusion
We present in this setion some theoretial and numerial results on the optimal ontrol problem
introdued in the previous setion. We use either its form (43) or (53); the data are
T > 2τ > 0, R0, p0 ≥ 0, α, β > 0, γ ≥ 0, u¯, v¯, U¯ , V¯ ≥ 0.
The rst eigenvalue λ is determined by (23).
5.1 Existene and optimality onditions
We begin with a result of existene of an optimal protool of drugs administration. It relies on
the fat that the dynamis is ane w.r.t. the ontrols. We do not have uniqueness in general.
Proposition 5.1. There exists at least one optimal protool of drugs administration (uˆ, vˆ) with
assoiated state (Rˆ, . . . , Vˆ ).
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Proof. The value of problem (53) is non-negative; let (uk, vk, Rk, . . . , V k) be a minimizing se-
quene. Observe that (uk, vk) is bounded in L∞, and (Rk, . . . , V k) is bounded and equiontinuous
on [0, T ]. Then by Banah-Alaoglu theorem and Arzelà-Asoli theorem, there exists (uˆ, . . . , Vˆ )
suh that, up to a subsequene,
(uk, vk) ⇀ (uˆ, vˆ) and (Rk, . . . , V k)→ (Rˆ, . . . , Vˆ )
for the weak ∗ topology in L∞ and the uniform topology in C0, respetively. Sine the dynamis
is ane w.r.t. the ontrols, (uˆ, . . . , Vˆ ) satises (44)-(52). The bounds and the nal onstraints
are also satised, and the objetive funtion is minimized by onstrution.
The seond result says that it is optimal to administrate as muh of ytotoxi as possible. It
implies uniqueness of the optimal protool of ytotoxi administration when it is not onstrained
by a maximal umulative dose. The onstrained ase will be studied numerially later.
Proposition 5.2. Let (uˆ, vˆ) be an optimal protool of drugs administration. Then∫ T
0
uˆ(t)dt = min
{
u¯T, U¯
}
.
In partiular, if U¯ ≥ u¯T , then uˆ(t) = u¯ a.e. on (0, T ).
Proof. If Uˆ(T ) < min
{
u¯T, U¯
}
, then there exists an admissible u suh that u ≥ uˆ, u 6= uˆ. The
result follows from the fat that (2)-(4) is monotone w.r.t. u ∈ L∞(0, T ).
Next we state rst-order optimality onditions, in the form of Pontryagin's minimum priniple
and where we highlight that the dynamis is ane w.r.t. the ontrols.
Proposition 5.3. Let (uˆ, vˆ) be an optimal protool of drugs administration. Then there exists
(a, b) ∈ W 1,∞(0, T ;R1) suh that, for a.a. t ∈ (0, T ),
(uˆ(t), vˆ(t)) ∈ argmin
{
a(t)u+ b(t)v :
0 ≤ u ≤ u¯
0 ≤ v ≤ v¯
}
.
Proof. We apply Pontryagin's minimum priniple to the delayed problem (53). It an be done
either diretly [14℄, or after Guinn's transformation [12, 13℄ into an optimal ontrol problem of
ordinary dierential equations [8℄. The minimized funtion is linear w.r.t. (u, y) at all time
beause the dynamis is ane w.r.t. the ontrols. See Appendies A.1 and A.2 for the preise
statement of Pontryagin's minimum priniple and the expression of oeients a and b.
Then we expet, in the sense of the following orollary, the optimal protools to be bang-bang,
i.e. on their bounds.
Corollary 5.4. For a.a. t ∈ (0, T ),
uˆ(t) =
{
0 if a(t) > 0
u¯ if a(t) < 0
and vˆ(t) =
{
0 if b(t) > 0
v¯ if b(t) < 0
.
It is sometimes possible to determine the sign of b, and then the value of vˆ.
Proposition 5.5. Let V¯ ≥ v¯T and let (uˆ, vˆ) be an optimal protool of drugs administration.
Then there exists ε > 0 suh that
vˆ(t) =
{
0 a.e. on (T − ε, T ) if λ < 0
v¯ a.e. on (T − ε, T ) if λ > 0
.
Proof. It is important here to have Pontryagin's minimum priniple with normal multipliers. See
Appendix A.2 for the determination of the sign of b.
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5.2 Optimal protools
We use BOCOP [9℄ to solve numerially the undelayed optimal ontrol problem obtained by
Guinn's transformation [12, 13℄ of the delayed problem (53). We disuss here the optimal protool
(uˆ, vˆ), with assoiated state (Rˆ, . . . , Vˆ ), found numerially in dierent situations; we dene the
minimal and maximal proliferating phase balanes respetively by
δu¯ := 2e
−(γ2τ+u¯τ) − 1, δ0 := 2e
−γ2τ − 1.
Note that δu¯ ≤ δ0, the latter having the same sign as λ by (23).
The ase δ0 ≤ 0 orresponds to a situation where the proliferating phase globally kills ells,
even without the administration of any ytotoxi; λ ≤ 0 and then there is no natural growth of
the leukemi ell population: this is not a aner situation. It ould be seen that in this ase, it is
optimal to give no ytostati: vˆ(t) = 0 a.e. on (0, T ), beause the higher the global introdution
rate, the greater the loss of ells.
0 0
1
2
3
4
5
6
0 1 2 3 4 T= 5
Figure 3: An optimal protool with 0 ≤ δu¯ and limited ytotoxi. We onsider a maximal
umulative dose of ytotoxi U¯ = 2 days·u¯, whereas T = 5 days, τ = 1 day; the other parameters
are given in Appendix A.3. In addition to the optimal protool of drugs administration (uˆ, vˆ),
the assoiated total sub-population Pˆ2 is plotted.
The ase 0 ≤ δu¯ orresponds to a situation where the proliferating phase globally produes
ells, even with the administration of a maximum of ytotoxi; this is a very severe aner
situation. By Lemma 5.2, it is optimal to administrate as muh of ytotoxi as possible; therefore
we onsider a nontrivial onstraint (41) on the umulative dose of ytotoxi with 0 < U¯ < u¯T ,
and no onstraint on the ytostati. We observe in Figure 3 that the optimal protool of ytotoxi
administration is bang-bang, with uˆ(t) = u¯ a.e. when the total sub-population Pˆ2 (on whih the
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ytotoxi is ating) is relatively high. And ontrary to Setion 4.1 and Figure 2, the optimal
protool of ytostati administration is now vˆ(t) = v¯ a.e. on (0, T ), beause the lower the global
introdution rate, the smaller the gain of ells.
The ase δu¯ < 0 < δ0 orresponds to a situation where the proliferating phase globally
produes ells in absene of drugs, and the administration of ytotoxi an make it globally kill
ells; this is the most interesting situation.
0 0
1
2
3
4
5
6
0 1 2 3 4 T= 5 6 7
Figure 4: An optimal protool of with δu¯ < 0 < δ0. We onsider no onstraint on the umulative
dose of ytotoxi, T = 5 days, τ = 1 day; the other parameters are given in Appendix A.3. The
protool of ytotoxi administration is xed to the optimal uˆ(t) = u¯ a.e. on (0, T ) and is not
plotted; the solid lines (resp. the dash lines) represent the optimal protool (resp. the 0-onstant
protool) of ytostati administration and the assoiated total population.
First we onsider no onstraint on the umulative doses of the drugs. The optimal protool
of ytotoxi administration is again uˆ(t) = u¯ a.e. on (0, T ) and we do not plot it in Figure 4.
We observe that the optimal protool of ytostati administration is bang-bang, with vˆ(t) = 0
a.e. rst and vˆ(t) = v¯ a.e. seond. For omparison, we also plot the 0-onstant protool and the
assoiated total population, whih is slightly lower than for the optimal protool at time T , but
quikly beomes higher. The swith in the optimal protool of ytostati administration an be
understood as follows: the resting ells whih are introdued into the proliferating phase at time
t ∈ (0, T − 2τ) will have a proliferating phase whose balane is δu¯ < 0, whereas those introdued
at time t ∈ (T − τ, T ) will have a proliferating phase whose balane is δ0 > 0; it is therefore of
interest to have a high global introdution rate during (0, T−2τ) and a low one during (T−τ, T ).
Reall that we do not ontrol diretly the fration of inhibited ells k, but the inhibition rate v.
Note that by Proposition 5.5, we expeted to have vˆ(t) = v¯ a.e. at the end.
Seond we add a nontrivial onstraint on the umulative dose of ytotoxi only, as in the ase
of Figure 3. Again, the optimal protool of ytotoxi administration in Figure 5 is bang-bang,
with uˆ(t) = u¯ a.e. when the total sub-population Pˆ2 is relatively high. The optimal protool of
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Figure 5: An optimal protool with δu¯ < 0 < δ0 and limited ytotoxi. We onsider a maximal
umulative dose of ytotoxi U¯ = 2 days·u¯, whereas T = 5 days, τ = 1 day; the other parameters
are given in Appendix A.3. In addition to the optimal protool of drugs administration (uˆ, vˆ),
the assoiated total sub-population Pˆ2 is plotted.
ytostati administration vˆ is also bang-bang, and its struture an be understood similarly to
one of Figure 4: it is of interest to have a low global introdution rate if the ells whih are just
introdued are going to have a proliferating phase whose balane is positive, in partiular if a
time τ later, uˆ = 0 a.e. on a long enough interval; and it is also of interest to have a high global
introdution rate a time τ before the intervals where uˆ = u¯ a.e., in order for the ytotoxi to be
eient. Note that in this interpretation, uˆ depends on Pˆ2, whih depends on vˆ, whih depends
on uˆ.
5.3 Conlusion
The issue of nding good protools of drugs administration in leukemi ell ultures has been
formulated as an optimal ontrol problem, where the population dynamis is eventually redued
to a delay dierential system. It has to be noted that the denition of the objetive funtion
for this optimization problem is a nontrivial part of the modeling, and that it might still be
improved if we ould nd expliitly the limit I∞ in Lemma 3.10. This approah is dierent from
[7℄, where the objetive funtion is the Floquet eigenvalue of a periodi problem.
A few optimal protools have been presented to illustrate dierent behaviors, whih are not
always intuitive. Optimal protools in general have not been synthesized; the dimension 7 of the
dierential system and the fat that the adjoint state equations are with advaned arguments
have to be added to the omplexity desribed in [16℄ for ombined treatments. Nevertheless, it
is not exluded to get further results on bang-bang and singular ontrols, as in [16, 17℄, from the
analysis started in Appendix A.2.
Estimated parameters are needed for medial appliation and are to be published [4℄. The
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optimal ontrol problem being set and numerially implemented, it ould suggest in vitro pro-
tools to the biologists, and maybe answer questions of the liniians. It ould also simulate
experiments longuer than 5 days, whih are ompliated to arry out for pratial reasons. For
in vivo modeling, pharmaokineti-pharmaodynami (PK-PD) would have to be added, as in
[5, 16, 17℄.
A Appendix
A.1 Pontryagin's minimum priniple
We onsider problem (53) and its dynamis (44)-(51). We denote by R0, R1, and R2 the argu-
ments of the state variable R with a delay 0, τ , and 2τ , respetively; we denote similarly the
dierent arguments of all the undelayed and delayed state and ontrol variables. We then dene
the following funtions of t and
(u0, u1, v0, R0, R1, R2, P˜ 0, P˜ 02 , k
0, k1, k2, y0, U0, V 0)
by
FR(t, ·) :=
{
−(1− k0)βR0 + p0(2τ − t)2e
−γt−y0
if t < 2τ
−(1− k0)βR0 + (1− k2)(λ + β)R2eλ2τ−y
0
if t > 2τ
FP˜ (t, ·) :=

λP˜ 0 − u0P˜ 02 + (1− k
0)(λ + β)R0
−p0(2τ − t)2e
−γt−y0
if t < 2τ
λP˜ 0 − u0P˜ 02 + (1− k
0)(λ + β)R0
−(1− k2)(λ+ β)R2eλ2τ−y
0
if t > 2τ
FP˜2(t, ·) :=

(λ− u0)P˜ 02 + p0(τ − t)2e
−γt−(λ+γ)τ
−p0(2τ − t)2e
−γt−y0
if t < τ
(λ− u0)P˜ 02 + (1− k
1)(λ+ β)R1eλτ
−p0(2τ − t)2e
−γt−y0
if τ < t < 2τ
(λ− u0)P˜ 02 + (1− k
1)(λ+ β)R1eλτ
−(1− k2)(λ+ β)R2eλ2τ−y
0
if t > 2τ
Fk(t, ·) := v
0(1− k1)− αk
0 Fy(t, ·) :=
{
u0 if t < τ
u0 − u1 if t > τ
FU (t, ·) := u
0 FV (t, ·) := v
0
The system (44)-(51) an now be written as
dx
dt
(t) = Fx
(
t, u(t), u(t− τ), v(t), R(t), R(t − τ), R(t− 2τ), P˜ (t), P˜2(t),
k(t), k(t− τ), k(t− 2τ), y(t), U(t), V (t)
)
for x ∈ {R, P˜ , P˜2, k, y, U, V } and for a.a. t ∈ (0, T ).
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We dene the Hamiltonian and the nal point Lagrangian respetively as follows: given
q = (qR, qP˜ , qP˜2 , qk, qy, qU , qV ) ∈W
1,∞(0, T ;R7), let
H [q](t, ·) :=
∑
x
qx(t)Fx(t, ·), x ∈ {R, P˜ , P˜2, k, y, U, V },
and given Ψ = (ΨU ,ΨV ) ∈ R
2
, let
Φ[Ψ](·) := R0 + P˜ 0 +ΨU (U
0 − U¯) + ΨV (V
0 − V¯ ),
where · stands again for (u0, u1, v0, R0, R1, R2, P˜ 0, P˜ 02 , k
0, k1, k2, y0, U0, V 0).
Given a protool of drugs administration (uˆ, vˆ), and (Rˆ, . . . , Vˆ ) its assoiated state, we denote
by Ĥ [q](t) the evalution of H [q] at(
t, uˆ(t), uˆ(t− τ), vˆ(t), Rˆ(t), Rˆ(t− τ), Rˆ(t− 2τ), . . . , Vˆ (t)
)
,
by Φ̂[Ψ](T ) the evaluation of Φ[Ψ] at(
uˆ(T ), uˆ(T − τ), vˆ(T ), Rˆ(T ), Rˆ(T − τ), Rˆ(T − 2τ), . . . , Vˆ (T )
)
,
and similarly for their partial derivatives. We an now state Pontryagin's minimum priniple:
Theorem A.1. Let (uˆ, vˆ) be an optimal protool of drugs administration with assoiated state
(Rˆ, . . . , Vˆ ). Then there exist q ∈W 1,∞(0, T ;R7) and Ψ ∈ R2 suh that, for a.a. t ∈ (0, T ),
−
dqx
dt
(t) = Dx0Ĥ[q](t) + χ(0,T−τ)(t)Dx1Ĥ [q](t+ τ) qx(T ) = Dx0Φ̂[Ψ](T )
+ χ(0,T−2τ)(t)Dx2Ĥ [q](t+ 2τ), (54)
for x ∈ {R, P˜ , P˜2, k, y, U, V }; for a.a. t ∈ (0, T ),
Ĥ [q](t) + χ(0,T−τ)(t)Ĥ [q](t+ τ) ≤ H [q]
(
t, u, uˆ(t− τ), v, Rˆ(t), . . . , Vˆ (t)
)
+ χ(0,T−τ)(t)H [q]
(
t+ τ, uˆ(t+ τ), u, vˆ(t+ τ), Rˆ(t+ τ), . . . , Vˆ (t+ τ)
)
(55)
for all (u, v) ∈ [0, U¯ ]× [0, V¯ ]; and
ΨU ≥ 0, ΨU
(
Uˆ(T )− U¯
)
= 0,
ΨV ≥ 0, ΨV
(
Vˆ (T )− V¯
)
= 0.
Proof. This is Pontryagin's minimum priniple [8, 12, 14℄. Observe that problem (53) satises
a Mangasarian-Fromovitz ondition of qualiation if U¯ , V¯ > 0; we onsider the optimal ontrol
problem without the ontrol u (resp. v) if U¯ = 0 (resp. V¯ = 0), and it beomes qualied. Then
we get the existene of normal multipliers [8℄.
A.2 Proof of Propositions 5.3 and 5.5
By (54), qU ≡ ΨU and qV ≡ ΨV . Sine H [q] is ane w.r.t. (u
0, u1, v0), we derive Proposition 5.3
from the Hamiltonian minimum ondition (55), with
a(t) = Du0Ĥ[q](t) + χ(0,T−τ)(t)Du1Ĥ [q](t+ τ)
= ΨU − (qP˜ (t) + qP˜2(t))
ˆ˜
P2(t) + qy(t) + χ(0,T−τ)(t)qy(t+ τ),
b(t) = Dv0Ĥ[q](t)
= ΨV + qk(t)(1 − kˆ(t)).
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For Proposition 5.5, we need to determine the sign of b in a neighborhood of T . Let V¯ ≥ v¯T ;
onsidering the equivalent optimization problem without the onstraint on V , we an assume
that ΨV = 0. Sine 1− kˆ > 0, b has then the same sign as qk, whose adjoint equation (54) is
dqk
dt
(t) = qk(t)(vˆ(t) + α)− (qR − qP˜ )(t)βRˆ(t) + qP˜ (t)λRˆ(t)
+ χ(0,T−τ)(t)qP˜2 (t+ τ)(λ + β)Rˆ(t)e
λτ
+ χ(0,T−2τ)(t)(qR − qP˜ − qP˜2)(t+ 2τ)(λ + β)Rˆ(t)e
λ2τ−yˆ(t+τ)
for a.a. t ∈ (0, T ), and qk(T ) = 0.
Lemma A.2. Let c, d ∈ L∞(R) and w, z ∈ W 1,∞loc be suh that, for a.a. t,
w˙(t) = c(t)w(t) + d(t) w(T ) = w¯,
z˙(t) = d(t)e
∫
T
t
c(θ)dθ z(T ) = w¯.
Then w and z have the same sign.
Proof. Simply observe that
w(t) =
(
w¯ −
∫ T
t
d(s)e
∫
T
s
c(θ)dθds
)
e−
∫
T
t
c(θ)dθ
= z(t)e−
∫
T
t
c(θ)dθ.
Let f ∈ L∞(0, T ) be dened by
f(t) := −(qR − qP˜ )(t)β + qP˜ (t)λ+ χ(0,T−τ)(t)qP˜2 (t+ τ)(λ + β)e
λτ
+ χ(0,T−2τ)(t)(qR − qP˜ − qP˜2)(t+ 2τ)(λ + β)e
λ2τ−yˆ(t+τ)
and σ ∈ W 1,∞(0, T ) be suh that, for a.a. t,
σ˙(t) = f(t)Rˆ(t)e
∫
T
t
(vˆ(θ)+α)dθ σ(T ) = 0.
Then b has the same sign as σ. By the nal ondition of the adjoint equations (54), f(T ) = λ.
Sine f is left-ontinuous on T , there exists ε > 0 suh that f , and then σ˙, have the same sign
as λ on (T − ε, T ). Proposition 5.5 follows.
A.3 Parameters for the numerial resolutions
These parameters have not been estimated; some of them are xed in oherene with data from
the experiments desribed in the introdution [4℄, the others are hosen to explore dierent
situations.
Figure 2 The parameters are the following:
T = 5 days τ = 1 day (56)
R0 = 4× 10
5
ells p0(a) = 0.5× 10
5
ells× day−1 (57)
α = 1 day−1 β = 2 day−1 v¯ = 2 day−1 (58)
γ = 0.15 day−1 (59)
The proliferating phase balane is then 2e−γ2τ − 1 ≈ 0.48 > 0.
RR n° 8356
24 Xavier Dupuis
Figure 3 The parameters are the following: (56)-(58) and
γ = 0.05 day−1 u¯ = 0.2 day−1 U¯ = 2 days · u¯ (60)
Note that for these values, 0 < δu¯ ≈ 0.48 < δ0 ≈ 0.81. Solving numerially (23), we get λ ≈ 0.24
day
−1 > 0.
Figure 4 The parameters are the following: (56)-(58) and
γ = 0.05 day−1 u¯ = 1 day−1 (61)
Note that now, δu¯ ≈ −0.33 < 0.
Figure 5 The parameters are the following: (56)-(58),(61) and
U¯ = 2 days · u¯ (62)
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